A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 18 Jul 2018 Planned number of patients changed to 824.
- 18 Jul 2018 Planned End Date changed from 18 Oct 2018 to 31 Mar 2019.
- 18 Jul 2018 Planned primary completion date changed from 18 Sep 2018 to 31 Mar 2019.